Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma (NCT01924819)
A Randomised Phase II/III Trial of Preoperative Chemoradiotherapy Versus Preoperative Chemotherapy for Resectable Gastric Cancer
🩺 Plain-English Summary (8th-Grade Level)
Gastric cancer remains a significant global public health problem. Although in developed countries its incidence has dramatically decreased, on a worldwide scale it is still a leading cause of cancer-related deaths. Surgery is the only potentially curative treatment for gastric cancer. Although the survival rates for patients with early stage disease (stage 1A and 1B) are good, this subgroup of patients constitutes only 20% of those undergoing resection. The majority of patients will have locally advanced or metastatic disease at presentation, which has an extremely poor prognosis. The current five-year survival rate for gastric cancer in Western countries is approximately 20-30%, a figure that has improved little over the past 30 years. The intervention arm in TOPGEAR consists of pre-operative chemotherapy, pre-operative chemoradiotherapy, surgery and post-operative chemotherapy. The control arm consists of pre-operative chemotherapy, surgery and post-operative chemotherapy. The primary objective of TOPGEAR is to investigate whether the addition of chemoradiotherapy to chemotherapy is superior to chemotherapy alone in the neoadjuvant setting by improving pathological complete response rates in the first instance, and subsequently overall survival, in patients undergoing adequate surgery (D1+ dissection) for resectable gastric cancer.
Who can join: Review the eligibility criteria below.
Location: Calvary Mater Newcastle — Newcastle, New South Wales
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (59 Sites)
Showing the first 25 of 59 sites.
- Calvary Mater Newcastle — Newcastle, New South Wales
- Chris O Brien Lifehouse — Sydney, New South Wales
- Liverpool Hospital — Sydney, New South Wales
- Nepean Hospital — Sydney, New South Wales
- Prince of Wales Hospital — Sydney, New South Wales
- Royal North Shore Hospital — Sydney, New South Wales
- St George Hospital — Sydney, New South Wales
- Westmead Hospital — Sydney, New South Wales
- The Tweed Hospital — Tweed Heads, New South Wales
- Wollongong Hospital — Wollongong, New South Wales
- Princess Alexandra Hospital — Brisbane, Queensland
- Flinders Medical Centre — Adelaide, South Australia
- Royal Hobart Hospital — Hobart, Tasmania
- Launceston General Hospital — Launceston, Tasmania
- Geelong Hospital — Geelong, Victoria
- Austin Hospital — Melbourne, Victoria
- Monash Medical Centre — Melbourne, Victoria
- Peter MacCallum Cancer Centre — Melbourne, Victoria
- St Vincent's Hospital — Melbourne, Victoria
- Sunshine Hospital (Western Health) — Melbourne, Victoria
- Sir Charles Gairdner Hospital — Nedlands, Western Australia
- AZ Klina — Brasschaat,
- Universitair Ziekenhuis Antwerpen — Edegem,
- Hospital De Jolimont — La Louvière,
- U.Z Leuven Campus Gasthuisberg — Leuven,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Gastric Cancer
- A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors — Scottsdale, Arizona
- Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer — Los Angeles, California
- Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) — Baltimore, Maryland
- Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer — Baltimore, Maryland
- Study for AZD4360 in Participants With Advanced Solid Tumours — Santa Monica, California
- Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma — Tampa, Florida
Explore by condition: All Gastric Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.